Transgenic SIRT6 mice show improved glucose tolerance and reduced beta cell death, suggesting SIRT6 roles in aging.
Pancreatic β cells undergo senescence and loss during aging; however, the underlying mechanisms remain incompletely understood. This study aimed to investigate what sirtuin 6 (SIRT6) does during β cell aging. Pancreatic β-cell-specific SIRT6 transgenic mice (TgSIRT6) were generated for this study. DNA damage, cell death, and cell proliferation were analyzed in cell and mouse models. SIRT6 protein levels were decreased in pancreatic β cells during aging. TgSIRT6 mice exhibited less DNA damage and cell death including apoptosis, necroptosis, and pyroptosis in β cells than that in control mice. TgSIRT6 mice had increased total islet area and mass in pancreas compared to control mice. As a result, TgSIRT6 mice showed better glucose tolerance and glucose-stimulated insulin secretion than control mice. RRAD and GEM like GTPase 2 (REM2), an endogenouse inhibitor of high-voltage-activated calcium channels, was negatively regulated by SIRT6. Knockdown of Rem2 in INS-1 cells partially rescued the SIRT6 deficiency- and palmitic acids-induced DNA damage, lipid peroxidation, and cell death. Rem2 β-cell-specific knockout mice had less DNA damage and cell death in β cells than that in control mice. Our data suggest that SIRT6 is a critical anti-aging factor in pancreatic β cells and it can be a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: